Inactive Instrument

Press Releases Cleveland BioLabs, Inc. Nasdaq

Equities

US1858601032

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2021	Cleveland Biolabs : Cytocom Changing Name to Statera BioPharma	MT
2021	Cleveland Biolabs, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm	22-06-14	GL
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing	22-05-23	GL
Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products	22-05-13	GL
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone	22-04-27	GL
Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod	22-04-13	GL
Statera Biopharma, Inc. Files Form 12b-25	22-03-31	GL
Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering	22-03-24	GL
Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering	22-03-22	GL
CORRECTION -- Statera Biopharma Announces Proposed Underwritten Public Offering	22-03-22	GL
Statera Biopharma Announces Revised Preliminary Revenue and Financial Results of Fiscal Year 2021	22-03-08	GL
CORRECTION - Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19	22-03-02	GL
Statera Biopharma, Inc., Announces Central Institutional Review Board Approval of Phase 3 Clinical Trial for Pediatric Crohn’s Disease	22-02-15	GL
Statera Biopharma : to Participate in the Benzinga Healthcare Small Cap Conference	21-09-22	PR
Statera Biopharma : to Participate in the Cantor Virtual Global Healthcare Conference	21-09-21	PR
Cleveland Biolabs : OF RESTATED CERTIFICATE OF INCORPORATION (Form 8-K)	21-09-01	PU
CYTOCOM, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	21-08-17	AQ
Cleveland Biolabs : CYTOCOM, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	21-08-16	AQ
CYTOCOM, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	21-08-09	AQ
CYTOCOM, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	21-08-02	AQ
Cleveland Biolabs : CYTOCOM, INC. Financial Statements and Exhibits (form 8-K/A)	21-07-30	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cleveland BioLabs, Inc. Nasdaq

Equities

US1858601032

Press Releases

Filters